EcoDrugPlus

Dna Topoisomerase Ii Beta

Ensembl ID : ENSEEUG00000006225
Gene Symbol: TOP2B
1 External references
210 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSEEUG00000014227
Gene Symbol: EPHA3
1 External references
216 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSEEUG00000015691
Gene Symbol: FYN
1 External references
264 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSEEUG00000000226
Gene Symbol: GPR119
4 External references
176 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSEEUG00000004567
Gene Symbol: HCK
1 External references
206 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSEEUG00000011029
Gene Symbol: ITK
1 External references
208 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSEEUG00000011377
Gene Symbol: JAK1
1 External references
238 Possible Orthologues:

Janus Kinase 2

Ensembl ID : ENSEEUG00000011781
Gene Symbol: JAK2
1 External references
265 Possible Orthologues:

Kit Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSEEUG00000012595
Gene Symbol: KIT
1 External references
211 Possible Orthologues:

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSEEUG00000003058
Gene Symbol: KRAS
1 External references
203 Possible Orthologues:

Lck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSEEUG00000015940
Gene Symbol: LCK
1 External references
120 Possible Orthologues:

Malt1 Paracaspase

Ensembl ID : ENSEEUG00000000266
Gene Symbol: MALT1
1 External references
197 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).